StockNews.com Upgrades Esperion Therapeutics (NASDAQ:ESPR) to Buy

StockNews.com upgraded shares of Esperion Therapeutics (NASDAQ:ESPR - Free Report) from a hold rating to a buy rating in a report released on Saturday.

A number of other brokerages have also recently commented on ESPR. HC Wainwright reissued a "buy" rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research note on Wednesday, October 2nd. Needham & Company LLC cut their target price on Esperion Therapeutics from $8.00 to $6.00 and set a "buy" rating on the stock in a report on Tuesday, August 13th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $8.17.

Esperion Therapeutics Stock Performance

Shares of NASDAQ:ESPR traded up $0.04 during midday trading on Friday, hitting $2.10. 3,552,788 shares of the stock were exchanged, compared to its average volume of 3,274,429. The business's 50-day moving average price is $1.85 and its 200 day moving average price is $2.12. Esperion Therapeutics has a 12 month low of $0.71 and a 12 month high of $3.40.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last announced its earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.10. The company had revenue of $73.83 million for the quarter, compared to the consensus estimate of $51.90 million. Equities research analysts anticipate that Esperion Therapeutics will post -0.04 earnings per share for the current year.

Institutional Investors Weigh In On Esperion Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ESPR. BOKF NA bought a new stake in Esperion Therapeutics during the second quarter worth $26,000. Traphagen Investment Advisors LLC purchased a new stake in Esperion Therapeutics during the third quarter worth about $27,000. Xponance Inc. purchased a new stake in Esperion Therapeutics during the second quarter worth about $28,000. CVI Holdings LLC bought a new stake in Esperion Therapeutics in the first quarter worth about $37,000. Finally, Sivia Capital Partners LLC purchased a new position in Esperion Therapeutics in the second quarter valued at about $44,000. Hedge funds and other institutional investors own 47.39% of the company's stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.